Dr. Steven J. Lee, co-chair of Kenyon & Kenyon LLP’s Chemical/Life Sciences practice group, has twenty-five years of experience representing companies in intellectual property matters. As an experienced chemist, Dr. Lee is adept at advising companies in the pharmaceutical, biotechnology, chemical and bioinformatics industries on all areas of patents, including litigation, interferences, counseling, and prosecution.
Dr. Lee is recognized by several legal referral guides as being one of the leading life sciences attorneys in the world. The Legal 500 United States describes him as possessing “extensive knowledge of patent litigation in the life sciences sector.” Likewise, the 2012 edition of Chambers Global quotes his clients as reporting that Dr. Lee has “incredible prowess in IP – he is smart and very capable.” He has been named by U.S. News – Best Lawyers as one of the best New York patent law attorneys (2013) and named a New York "IP Star" by Managing Intellectual Property (2013). In addition, Dr. Lee is recognized as one of the world’s leading patent litigators by IAM 1000 – The World’s Leading Patent Practitioners where a client anonymously stated that Dr. Lee is “A tenacious lawyer who always does his homework” (2013). He has also been recognized by Chambers USA in the area of “IP: Patent” (2013), New York Super Lawyers (2012), and The International Who’s Who of Business Lawyers (2013).
Dr. Lee brings his technical acuity to bear in a wide range of client matters. His patent litigation experience literally extends to products ranging from A to Z: generic versions of Allegra, Augmentin, Claritin, Gemzar, Hytrin, Neurontin, Oxycontin, Paxil, Procardia, Relafen, Sarafem, Seldane, Ticlid, Zantac and Zithromax; brand name pharmaceuticals including Duracef, Kadian, Lovenox, Ortho-Cyclen and Xalatan; as well as monoclonal antibodies for septic shock and against stem cells. Equally adept at representing clients whose innovations involve patents on bioinformatics and alternative methods for drug delivery, Dr. Lee has litigated cases involving DNA synthesis machines and transdermal drug delivery systems.
Dr. Lee’s experience gained while practicing chemistry for eleven years and teaching as an associate professor of Chemistry at Fordham University has enabled him to develop sophisticated litigation strategies for clients engaged in chemical related litigations involving coatings for aluminum cans, paints for automobiles, and striped toothpaste. Dr. Lee also prosecutes patent applications in the chemical and life sciences areas, counsels inventors and patent owners on the scope and validity of their intellectual properties, and advises clients introducing new products and services as to any potential for infringement of the patent rights of others.
Dr. Lee is frequently invited to speak at conferences around the world on topics pertaining to intellectual property law and litigation. He speaks annually at Fordham University’s School of Law Conference on International IP Law and Policy. In addition, he has spoken at American Conference Institute’s Annual Paragraph IV Disputes and Maximizing Pharmaceutical Patent Life Cycles conferences. He has also spoken at a webinar hosted by the Intellectual Property Owners Association; a seminar hosted by the Fordham IP Institute; a seminar focused on “Navigating the Challenges of ANDA Disputes” during the Law360 Expert Insight Series; the New York Biotechnology Association’s Annual Meetings; the Institute for International Research’s Annual Generics Summit; a Pharmaceutical Law 2006 seminar entitled “Across the Product Life Cycle” hosted by the Practicing Law Institute; and GphA’s Annual Policy Conference: The Generic Industry Event of the Season.
Dr. Lee is also a prolific author whose recent publications include an article in Intellectual Asset Management magazine on “Waxman-Hatch Litigation Strategies For Generic And Brand Companies” (2010); the chapter in the ABA’s Patent Litigation Strategies Handbook on “Waxman-Hatch Litigation From the Perspective of the Generic Pharmaceutical Industry” (2010); the chapter in BNA’s International Pharmaceutical Law and Practice, 2nd Ed. (2009) on U.S. patent law; and an article in the Fordham Intellectual Property, Media & Entertainment Law Journal, Vol. XVII, number 4, pages 915-932 (2007) on the U.S. law of obviousness.